Water-Soluble Version of Etoposide Now Available

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 10
Volume 5
Issue 10

PRINCETON, NJ--Bristol-Myers Squibb Company has received FDA clearance to market Etopophos (etoposide phosphate) for injection, a new water-soluble version of its anticancer drug VePesid (etoposide).

PRINCETON, NJ--Bristol-Myers Squibb Company has received FDA clearanceto market Etopophos (etoposide phosphate) for injection, a newwater-soluble version of its anticancer drug VePesid (etoposide).

Etopophos can be administered in as few as 5 minutes, representinga marked advantage over the 30- to 60-minute infusion time requiredfor VePesid, the company said.

Etopophos can also be given to patients in higher concentrationsthan VePesid, reducing by up to 1/50th the fluid volume infused.

The new version of the drug has the same indication as VePesid:to be used in combination with other approved chemotherapy agentsas first-line treatment in patients with small-cell lung cancerand in combination with other approved chemotherapy agents inpatients with refractory testicular tumors who have already receivedappropriate surgery, chemotherapy, and radiotherapy.

"This new version of etoposide offers greater convenienceto both patients and the medical professionals who care for them,"said Michelle Daniels, MD, director, Medical Information, Bristol-MyersSquibb Oncology. "Patients may now spend a lot less timein the clinic receiving their treatment."

Articles in this issue
Anesthetic Interventions Rise When Anesthesiologists Join the Pain Team
Worldwide UN Survey Shows Many Impediments to Morphine Availability
Case-Based Pain Curriculum Used in Canadian Schools
Effective Physician and Patient Communication Is Essential in Palliative Care
Withdrawal Syndrome After Stopping Opioids Is Not Evidence of Drug Dependence, WHO Committee Says
Brief Pain Inventory and Faces Scale Perform Well in a Group of Low-Income, Primarily Black Cancer Patients
Whole-Body Vibration Within Specified Frequency Range May Provide Pain Relief
Pain Descriptions May Predict Presence of Neuropathic Pain
Neurotoxicity Related to High-Dose Opioid Therapy Can Be Managed
Epidural Morphine Relieves Pain in Advanced Cancer, But May Not Influence Quality of Life
Dr. Payne Urges Strategies to Overcome Barriers to Use of Cancer Pain Guidelines
Program Trains Community Opinion Leaders in Principles of Pain Control
Postmarketing Surveillance for Drug Abuse Supports Nonscheduled Status of Tramadol
Consider Quality of Life and Patient Preference When Choosing Pain Relief
Patients' Pain Anxiety Levels Vary Depending on the Type of Pain, the Patient's Gender, and Pain Duration
Related Videos
Ghayas C. Issa, MD, an expert on acute myeloid leukemia
Ghayas C. Issa, MD, an expert on acute myeloid leukemia
Administering immunotherapy following surgery in patients with early-stage triple-negative breast cancer does not appear to be as effective as beginning with neoadjuvant treatment, says Peter Schmid, MD, PhD.
Heather A. Parsons, MD, MPH, says she is excited about HER2 as a biomarker and investigating the biology of metastatic breast cancer with a minimally invasive liquid biopsy platform.
Related Content
Treatment with atezolizumab among patients with HER2-positive breast cancer in the phase 3 APTneo Michelangelo trial produces no major tolerability issues, says Luca Gianni, MD.

Atezolizumab Combo Numerically Improves pCR in HER2+ Operable Breast Cancer

December 9th 2023
Article

Treatment with atezolizumab among patients with HER2-positive breast cancer in the phase 3 APTneo Michelangelo trial produces no major tolerability issues, says Luca Gianni, MD.

Govindarajan Narayanan, MD, speaks to the potential time-saving advantages of using the Epione robot for microwave ablation, cryoablation, and other surgical strategies in patients with liver cancer and other tumors.

Adapting to a Robotic Workstation for Image-Guided Liver Cancer Surgery

December 4th 2023
Podcast

Govindarajan Narayanan, MD, speaks to the potential time-saving advantages of using the Epione robot for microwave ablation, cryoablation, and other surgical strategies in patients with liver cancer and other tumors.

Latin American patients appear more likely to be diagnosed with aggressive early-stage breast cancer based on factors including metabolics and genetics, according to findings from the FLEX study.

Metabolism, Genetics May Impact Tumor Biology in Breast Cancer Populations

December 8th 2023
Article

Latin American patients appear more likely to be diagnosed with aggressive early-stage breast cancer based on factors including metabolics and genetics, according to findings from the FLEX study.

Personalized therapy tailored for mutation status is something to expect in the coming years for colorectal cancer treatment, notes Tanios S. Bekaii-Saab, MD.

Tanios S. Bekaii-Saab, MD, Speaks to Expanding Horizons in CRC Treatment

November 27th 2023
Podcast

Personalized therapy tailored for mutation status is something to expect in the coming years for colorectal cancer treatment, notes Tanios S. Bekaii-Saab, MD.

Investigators observe no new safety signals with trastuzumab emtansine as a treatment for HER2-positive breast cancer after 8 years of follow-up in the phase 3 KATHERINE study.

T-DM1 Improves OS/iDFS Vs Trastuzumab in HER2+ Breast Cancer

December 8th 2023
Article

Investigators observe no new safety signals with trastuzumab emtansine as a treatment for HER2-positive breast cancer after 8 years of follow-up in the phase 3 KATHERINE study.

Patients who are under the age of 17 with invasive mucormycosis or invasive aspergillosis, which is an AE of leukemia, can now receive isavuconazonium sulfate following FDA approval

FDA Approves Isavuconazonium Sulfate for Pediatric Fungal Infections

December 8th 2023
Article

Patients who are under the age of 17 with invasive mucormycosis or invasive aspergillosis, which is an AE of leukemia, can now receive isavuconazonium sulfate following FDA approval